Valuation: Ipsen

Market Cap 13.27B 15.3B 12.43B 11.37B 21.47B 1,457B 21.75B 145B 57.07B 728B 57.43B 56.18B 2,423B P/E 2026 *
13.4x
P/E 2027 * 14.2x
Enterprise Value 11.89B 13.7B 11.13B 10.18B 19.22B 1,305B 19.47B 130B 51.11B 652B 51.43B 50.31B 2,170B EV / Sales 2026 *
2.65x
EV / Sales 2027 * 2.4x
Free-Float
40.65%
Yield 2026 *
0.95%
Yield 2027 * 0.95%
1 day+0.56%
1 week-3.77%
Current month-3.77%
1 month-4.05%
3 months-5.41%
6 months+17.88%
Current year+35.55%
1 week 153.1
Extreme 153.1
165
1 month 153.1
Extreme 153.1
171.8
Current year 116
Extreme 116
176.6
1 year 105.6
Extreme 105.6
176.6
3 years 88.05
Extreme 88.05
176.6
5 years 77.28
Extreme 77.28
176.6
10 years 35.52
Extreme 35.52
176.6
Manager TitleAgeSince
Chief Executive Officer 59 01/07/2020
Chief Executive Officer 57 01/01/2020
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 61 30/08/2005
Chairman 68 22/11/2010
Director/Board Member 69 01/06/2012
Change 5-day change 1-year change 3-year change Capi.($)
+0.56%-3.77% - - 15.3B
+1.89%+3.20%+59.70%+165.18% 1,062B
-0.24%+0.45%+50.64%+52.02% 619B
-0.95%-5.26%+24.23%+65.08% 431B
+1.73%+5.06%+49.14%+40.27% 358B
+1.06%-0.11%+35.91%+40.75% 293B
+1.26%-4.96%+9.64%+10.29% 247B
-0.73%+4.44%+42.22%+66.41% 219B
+3.86%-0.64%-1.39%-44.19% 200B
-0.68%-0.32%+18.66%+66.32% 162B
Average +0.92%-1.90%+32.08%+51.35% 399.14B
Weighted average by Cap. +0.63%-0.83%+41.12%+78.25%

Financials

2026 *2027 *
Net sales 4.49B 5.17B 4.2B 3.84B 7.25B 492B 7.35B 49.14B 19.28B 246B 19.41B 18.99B 819B 4.57B 5.27B 4.28B 3.92B 7.4B 502B 7.49B 50.11B 19.66B 251B 19.79B 19.36B 835B
Net income 1.01B 1.17B 948M 868M 1.64B 111B 1.66B 11.1B 4.35B 55.55B 4.38B 4.29B 185B 961M 1.11B 900M 823M 1.55B 105B 1.57B 10.52B 4.13B 52.69B 4.16B 4.07B 175B
Net Debt -1.39B -1.6B -1.3B -1.19B -2.24B -152B -2.27B -15.19B -5.96B -76.05B -6B -5.87B -253B -2.31B -2.66B -2.16B -1.98B -3.73B -254B -3.78B -25.3B -9.93B -127B -9.99B -9.77B -422B
Logo Ipsen
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (69.2%); - neuroscience (20.3%); - rare diseases (10.5%). At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide. Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).
Employees
5,535
Date Price Change Volume
07/08/26 160.90 -0.49% 0
06/08/26 €161.40 +1.51% 624
05/08/26 €159.00 +1.27% 36,155
04/08/26 €157.00 +2.55% 1,209
03/08/26 €153.10 -8.43% 452
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
161.90EUR
Average target price
163.87EUR
Spread / Average Target
+1.21%

Quarterly revenue - Rate of surprise